Acalabrutinib (mantle cell lymphoma; combination with bendamustine and rituximab) – Second addendum to Project A25-89

Report documents

1. Addendum

   Acalabrutinib (mantle cell lymphoma; combination with bendamustine and rituximab) – Second addendum to Project A25-89

   published on

   18.12.2025

   Document type

   PDF document, 313 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/G25-34

   Download file : Addendum (PDF document, 313 kB, DE, not accessible)

Additional information

Project details

Project no.

G25-34

Commission

Commission awarded on 11.11.2025 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Health Economics

Topic

Cancer

Note

If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.

DOI

https://doi.org/10.60584/G25-34

Connected Projects

1. Dossier assessment

   Acalabrutinib (mantle cell lymphoma; combination with bendamustine and rituximab) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A25-89

   Last updated

   18.12.2025

   Status: Commission completed